MiniMed Group, Inc. (MMED)
| Market Cap | 5.60B |
| Revenue (ttm) | 3.10B +14.3% |
| Net Income | -333.00M |
| EPS | -1.30 |
| Shares Out | 280.84M |
| PE Ratio | n/a |
| Forward PE | 32.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 910,671 |
| Open | 20.45 |
| Previous Close | 20.45 |
| Day's Range | 19.63 - 20.68 |
| 52-Week Range | 10.65 - 20.88 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.83 (+4.46%) |
| Earnings Date | Sep 1, 2026 |
About MMED
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company’s platform includes Automated Insulin Delivery (AID) systems for... [Read more]
Financial Performance
In fiscal year 2026, MiniMed Group's revenue was $3.10 billion, an increase of 14.25% compared to the previous year's $2.72 billion. Losses were -$333.00 million, 56.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MMED stock is "Strong Buy." The 12-month stock price target is $20.83, which is an increase of 4.46% from the latest price.
News
MiniMed Group Proxy statement: Proxy filing
MiniMed Group filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
MiniMed Group Proxy statement: Proxy filing
MiniMed Group filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
MiniMed announces Flex system shipping in the U.S. with Instinct sensor
MiniMed (MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott (ABT). For the first time, people with diabetes…
MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor
MiniMed Flex™ with Instinct, made by Abbott, combines discreet design, up to 15 days of sensor wear and proven automation to reduce the work and interruptions of diabetes management NORTHRIDGE, Calif....
MiniMed price target raised to $24 from $20 at BofA
BofA raised the firm’s price target on MiniMed (MMED) to $24 from $20 and keeps a Buy rating on the shares. The firm, which believes Medtronic (MDT) ownership has likely…
MiniMed initiated with a Buy at UBS
UBS initiated coverage of MiniMed (MMED) with a Buy rating and $25 price target While shares have been under pressure since the IPO earlier this year, investors are likely undervaluing…
MiniMed announces Medicare beneficiaries have access to Flex system
MiniMed (MMED) announced that Medicare and Medicare Advantage beneficiaries now have access to the MiniMed Flex system with its latest sensor portfolio. This milestone now makes the company’s smallest...
MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries
NORTHRIDGE, Calif., July 22, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Medicare and Medicare Advantage beneficiaries now have access to ...
MiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results
NORTHRIDGE, Calif., July 20, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it expects to report financial results on Tuesday, September 1, 2...
MiniMed adds David Endicott, Linnea Burman to board of directors
MiniMed (MMED) announced that David Endicott and Linnea Burman have joined its Board of Directors, effective June 29, expanding the Board from nine to 11 members. Endicott will serve as…
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depth NORTHRIDGE, Calif., June 29, 2026 /PRNew...
MiniMed launches Instinct sensors in Europe
MiniMed (MMED) announced the commercial launch in Europe of both the MiniMed 780G system integrated with the Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor.
MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes
MiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company's portfolio NORTHRIDGE, Cali...
MiniMed announces commercial launch of MiniMed Flex system in the U.S.
MiniMed (MMED) announced its first commercial launch of the MiniMed Flex system in the U.S.- its first app-controlled pump and the company’s smallest insulin pump yet. The system launches with…
MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.
People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor NORTHRIDGE, Calif., June 17, 2026 /PRNewswire/ -- MiniMe...
MiniMed Group Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
AID systems are driving market growth, with new product launches and a robust pipeline supporting both U.S. and global expansion. The company leverages an integrated technology platform, direct commercial presence, and disciplined financial strategy to maintain competitive advantage and deliver sustained growth.
MiniMed Group Slides: Investor presentation
MiniMed Group has posted slides in relation to its latest quarterly earnings report, which was published on June 6, 2026.
MiniMed price target lowered to $22 from $26 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on MiniMed (MMED) to $22 from $26 and keeps an Overweight rating on the shares following the first earnings report…
MiniMed Group Earnings Call Transcript: Q4 2026
Record fiscal 2026 revenue surpassed $3 billion, with 8% organic growth and strong international performance. New product launches and pipeline advancements underpin a 10% organic growth outlook for FY 2027, with EBITDA margin expansion expected.
MiniMed Group Earnings release: Q4 2026
MiniMed Group released its Q4 2026 earnings on June 3, 2026, summarizing the period's financial results.
MiniMed Group Slides: Q4 2026
MiniMed Group has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 3, 2026.
MiniMed Group Annual report: Q4 2026
MiniMed Group has published its Q4 2026 annual report on June 3, 2026.
MiniMed announces expanded ketone sensor agreement with Abbott
MiniMed (MMED) announced an expanded agreement with Abbott (ABT) to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems. Thes...
MiniMed reports Q4 EPS (68c), consensus (22c)
Reports Q4 revenue $837M, consensus $826.52M. “MiniMed (MMED) delivered a strong finish to our fiscal year, driven by strength in international markets and continued global adoption of the MiniMed 780...
MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott
Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in dia...